Previous cancer radiation treatment could lead to worse breast cancer survival
Patients who had previous radiation treatments may benefit from tailored breast cancer treatment
Register for free to listen to this article
Listen with Speechify
0:00
5:00
SACRAMENTO, Calif.—A study has found that among premenopausal women with breast cancer, those who were previously treated with radiation for a primary childhood, adolescent or young adult cancer had worse breast cancer-specific survival rates.
The study, published in Cancer Epidemiology, Biomarkers & Prevention, was authored by Candice A. Sauder, M.D., who is surgical oncologist at the University of California (UC) Davis Comprehensive Cancer Center.
“We traditionally use similar therapies for primary breast cancer and second primary breast cancer, and base our treatment approaches on specific prognostic factors,” said Sauder. “Our results suggest that breast cancer-related survival is significantly decreased among all survivors of childhood, adolescent and young adult cancer who were treated with radiation therapy and then develop breast cancer, even in the setting of early-stage breast cancer and other characteristics that are considered good prognostic factors. As such, we may need to tailor our treatment strategy for women with a second primary breast cancer.”
Treatments for many common childhood and adolescent/young adult (AYA) cancers incorporate radiation therapy, which is a risk factor for second primary breast cancer. Second primary breast malignancies in younger women who had received prior radiation therapy have unique clinical characteristics, according to Sauder. But it’s unknown whether such features are related to prior radiation treatments, or to premenopausal status.
To better understand how radiation treatment used in the primary setting affects the clinical characteristics of second primary breast cancers in younger women, Sauder and colleagues analyzed data from the California Cancer Registry, using multivariable Cox proportional hazards regression.
The researchers looked at data from women ages 12 to 50 (to capture premenopausal breast cancer based on approximations of age at menarche and menopause) diagnosed with primary (107,751 women) or second primary breast cancer (1,147 women) between January 1, 1988, and December 31, 2014. Patients with second primary breast cancer were limited to those who had had a first primary cancer treated with radiation between the ages of 12 and 39.
The researchers compared demographic and clinical factors between women with second primary breast cancer, and those who had primary breast cancer. They compared breast cancer-specific survival between these groups, both collectively and for specific subgroups — including age, race/ethnicity, lymph node involvement, hormone receptor status and HER2 status.
Overall, compared with premenopausal women with primary breast cancer, the women with second primary breast cancer who had previously been treated with radiation were more likely to be Hispanic or Black. They also had earlier stage tumors, higher grade tumors, cancer without lymph node involvement and tumors that were hormone receptor-negative. Women with second primary breast cancer in this cohort had roughly twice the risk of breast cancer-specific death, compared with women with primary breast cancer.
Researchers discovered that breast cancer-specific survival among women with second primary breast cancer previously treated with radiation was significantly worse for all of the subgroups that were considered. Of note, subgroups of women who typically have a better prognosis in the primary breast cancer setting — like women with hormone receptor-positive tumors, tumors without lymph node involvement, stage I disease and women of Asian or Pacific Island ethnicity — experienced worse survival after a second primary breast cancer.
“We found that the negative impact of second primary breast cancer among women previously treated with radiation was particularly strong in subgroups of patients that have superior survival after primary breast cancer. It will be important to prospectively evaluate how certain treatments, such as specific radiation fields or chemotherapeutic agents, can affect second primary breast cancer outcomes,” Sauder explained.
Women with second primary breast cancer previously treated with radiation had over twice the risk of breast cancer-specific mortality if they had stage I disease, and nearly twice the risk of breast cancer-specific mortality if they had stage II or stage III disease, compared to women whose primary breast cancer was in the same stage. Similarly, women in this cohort had roughly 2.4 times the risk of breast cancer-specific mortality if they had tumors without lymph node involvement, and roughly 1.7 times the risk of breast cancer-specific mortality if they had tumors with lymph node involvement, compared with women with primary breast cancer who had the same lymph node involvement status.
“BCSS [breast cancer-specific survival] is significantly decreased among all survivors of childhood and AYA cancer treated with radiotherapy that develop a secondary breast cancer, including women with good prognostic features,” the study abstract notes. “Therefore, we may need to consider alternative and even more aggressive treatment in what were considered low-risk populations previously.”
Study limitations include a lack of comorbidity data and genetic information — including BRCA mutation status — which can influence treatment decisions, and which may affect second primary breast cancer risk.
